Start with HIV infection, then reuse UniProt P04608 as the stable protein anchor across project notes and exports.
CHEMBL4011 Target Snapshot
Protein Tat · SINGLE PROTEIN · Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Protein Tat shows clinical signal disease relevance led by HIV infection. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P04608. Start with HIV infection, then reuse UniProt P04608 as the stable protein anchor across project notes and exports.
Protein Tat shows clinical signal disease relevance led by HIV infection. 1 linked drug remains visible in the same block.
Start review with HIV infection because it currently carries clinical signal support. Linked drugs include RO-24-7429. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProtein Tat
Review this target as Protein Tat, mapped to UniProt P04608. Sequence length is 86 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Protein Tat as ChEMBL target CHEMBL4011, mapped to UniProt P04608. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Protein Tat is the right protein anchor across sources, using UniProt P04608 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Protein Tat |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1) |
| UniProt | P04608 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Protein Tat |
| UniProt Accession | P04608 |
| Component Type | Protein |
| Sequence Length | 86 aa |
Protein Tat
How to read this target
Review this target as Protein Tat, mapped to UniProt P04608. Sequence length is 86 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Protein Tat shows clinical signal disease relevance led by HIV infection.
How to read disease relevance
Start review with HIV infection because it currently carries clinical signal support. Linked drugs include RO-24-7429. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL483254 | 6.89 | EC50 | 130.0 | Approved |
| CHEMBL343448 | 6.66 | EC50 | 220.0 | Approved |
| CHEMBL4526214 | 6.1 | EC50 | 800.0 | Preclinical |
| CHEMBL4446565 | 6.05 | EC50 | 900.0 | Preclinical |
| CHEMBL1075826 | 6.05 | IC50 | 900.0 | Preclinical |
| CHEMBL609729 | 6.0 | EC50 | 1000.0 | Preclinical |
| CHEMBL4457218 | 5.92 | EC50 | 1200.0 | Preclinical |
| CHEMBL4439301 | 5.89 | EC50 | 1300.0 | Preclinical |
| CHEMBL4450433 | 5.89 | EC50 | 1300.0 | Preclinical |
| CHEMBL4531178 | 5.85 | EC50 | 1400.0 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 37 assays, 68 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 33 | 64 | 5.3 |
| single protein format | 4 | 4 | 5.4 |
Functional — 1 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |